1. Introduction {#sec0005}
===============

Coronavirus disease 2019(COVID-19), an infective disease caused by severe acute respiratory syndrome corona virus 2(SARS-COV-2) ([@bib0035]), was first identified in Wuhan, Hubei Province and then swept through other provinces in China and abroad, causing public attention. The World Health Organization (WHO) declared the emergence of SARS-COV-2 a public health emergency of international concern (PHEIC) on 30th January 2020 ([@bib0045]). On the 11th March 2020, WHO announced the COVID-19 pneumonia epidemic was "pandemic" worldwide. As of March 22th 2020, 81498 cases of novel coronavirus disease 2019(COVID-19) had been confirmed in China and other 223947 cases had been reported from more than 185 other countries. Isolation of cases and contact tracing were used to control COVID-19 in China, which had achieved great results ([@bib0010]). There have been no new confirmed cases in China for several consecutive days, and replaced with imported cases overseas. Cases confirmed in other countries increased rapidly.

Initial chest CT findings played a critical role in diagnosis of SARS-COV-2 infection and depicting the patterns and extent of the pulmonary abnormalities ([@bib0055], [@bib0040]). Since the outbreak of COVID-19, there were continuous literature regarding early chest CT imaging manifestations: most patients presented with multifocal ground-glass opacities (GGO) involving multiple lung lobes and had a predominantly subpleural distribution at admission ([@bib0040], [@bib0015], [@bib0055]). The extent of lesions had a tendency to be more extensive and the lesions had an increased density on follow-up CT scans ([@bib0030]). However, there is a lack of large sample data in different time for the imaging characteristics of COVID-19 pneumonia. The purpose of our study was to quantitatively assess dynamic changes of chest CT findings in the common type COVID-19 pneumonia cases and analyze the correlation between chest CT manifestations and laboratory test indexes.

2. Methods {#sec0010}
==========

2.1. Study design and participants {#sec0015}
----------------------------------

This study was conducted in accordance with the amended Declaration of Helsinki.

This was a multicenter study. The protocol was approved by independent ethics committees. Informed consent was signed by every patient. SARS-CoV-2 infection was confirmed by real time reverse transcriptase polymerase chain-reaction (RT-PCR) test using pharyngeal swab specimens. Confirmed COVID-19 pneumonia patients with negative CT findings or asymptomatic infection were excluded from this study. From January 10th 2020 to March 3th 2020, 307 eligible patients from 13 hospitals in Jiangsu were enrolled in the study. 628 CT scans of 307 patients were analyzed in the study.

The diagnostic criteria of clinical grading were as follows: mild, subtle or mild clinical symptoms without pneumonia finding on CT images; common, fever or respiratory symptoms, etc. and pneumonia on CT images; severe, with any of the followings: respiratory distress with respiratory rate (RR) \> 30/s, resting state oxygen saturation (SpO2) \< 93%, or oxygenation index (OI) (calculated by partial pressure of oxygen (PaO2)/fraction of inspired oxygen (FiO2) ≤300 mmHg (1mmHg = 0.133 kPa); critical severe, with any of the followings: respiratory failure and mechanical ventilation needed, shock, or combination with other organ failure needing ICU intensive need. Due to the relatively small number, patients of severe and critical severe type were excluded from the study. Only patients of common type were enrolled in the study.

Chest CT scans were divided into three groups based on the time interval between symptoms and CT scan. Group 1 contained 273 chest CT scans which were done within 1 week after symptom onset, Group 2 contained 255 chest CT scans which were done between 1 to 2 weeks after symptom onset, Group 3 contained 100 chest CT scans which were done between 2 to 3 weeks after symptom onset.

2.2. Data collection {#sec0020}
--------------------

All the clinical data on epidemiology, signs and symptoms, laboratory test results were extracted from electronic medical records.

2.3. CT Imaging acquisition {#sec0025}
---------------------------

Chest high-resolution CT(HRCT) was performed for all patients. All patients in the supine position were scanned with breath holding at the end of inhaling. The chest CT scanning was performed in GE Bright Speed Elite 16, SOMATOM Emotion, SOMATOM definition AS, Neusoft 16, PHLIPS MX-16, Philips 64-row spiral Ingenuity or the UNITED IMAGING Elite 16, with the scanning parameters as follows: tube voltage 120 kV, tube current 110 mA, pitch 1.0, rotation time ranging from 0.5s to 0.75s, slice thickness 5 mm, with section thickness of 1 mm or 1.5 mm for axial, coronal and sagittal reconstructions.

2.4. CT image analysis and quantification {#sec0030}
-----------------------------------------

HRCT images were independently reviewed by two radiologists with over 10-year experience who were blinded to the clinical data of the patients. Images were reviewed independently, and final decisions were reached by consensus. For disagreement between the two primary radiologist interpretations, a third radiologist with 10-year experience adjudicated a final decision.

Quantitative evaluation was made on the abnormal manifestations of chest HRCT imaging. The abnormal imaging signs including ground glass opacity(GGO), consolidation, fibrosis were quantified by two radiologists. Pulmonary fibrosis not related to COVID-19 pneumonia was ruled out. The radiologists estimated the lesion areas on each lung lobe as a percentage of the whole lung lobe, and the percentages in each lung lobe were scored using the following 6-grade scale: 0, absent; 1, 1 to 5%; 2, 6 to 25%; 3, 26 to 50%; 4, 51 to 75%; and 5, 76 to 100%. Scores from the whole lung were summarized to get the total scores of each lesion respectively. Distribution characteristics, shapes of the lesion, vascular enhancement sign, air bronchial sign, interlobular septal thickening, pleural thickening, pleural effusion and lymphadenopathy were observed and recorded.

2.5. Statistical analysis {#sec0035}
-------------------------

All statistical analyses were performed by Statistical Product and Service Software (SPSS Statistics, version 26.0, Chicago, IL, USA). Categorical data were described as frequency rates or percentages. Continuous data compatible to normal distribution were described by mean ± SD(standard deviation). Continuous data incompatible to normal distribution were described by median (25^th^ quantiles, 75^th^ quantiles). Mann-Whitney U test was used to test the differences of quantitative variables between two groups. Spearman rank correlation was used to test the association between the arterial blood gas (ABG) analysis results and chest CT scores. P-value \< 0.05 was considered statistically significant.

3. Results {#sec0040}
==========

3.1. Demography and clinical characteristics {#sec0045}
--------------------------------------------

307 patients of common type COVID-19 pneumonia were enrolled in the study, which included 164(53.4%) men and 143(46.6%) women. The ages were 46(33, 55) years old, ranging from 7 to 80 years old.. Fever (69.1%) and cough (62.8%) were the most common symptoms. 81(26.4%) patients had temperatures between 37.3 and 38 degrees Celsius, which was low fever. 103(33.6%) patients had temperatures between 38 and 39 degrees Celsius, which was middle fever. Dry cough Only 28(9.1%) patients had temperatures over 39 degrees Celsius, which was high fever. Anorexia was a common symptom, occurring in 111(36.2%) patients. Fatigue, pharyngeal discomfort and muscle soreness were the common symptoms occurred in over 10% patients. Chill, chest pain, short of breath, dyspnea, diarrhea, flustered, nasal congestion and runny nose, nausea and vomiting were also occurred in few cases (as shown in [Table 1](#tbl0005){ref-type="table"} ).Table 1Demography, clinical manifestation of 307 COVID-19 pneumonia patientsTable 1CharacteristicsN(%)Gender Male164(53.4%) Female143(46.6%)Age(y) Median (25th quantiles, 75th quantiles)46(33, 55)Epidemical history Hubei residence or travel122(39.7%) Close contact108(35.2%) Unclear77(25.1%)Fever212(69.1%) Low fever(37.3-38°C)81(26.4%) Middle fever(38-39°C)103(33.6%) High fever(\>39°C)28(9.1%)Cough193(62.8%) Dry cough122(39.7%) Expectoration71(23.1%)Anorexia111(36.2%)Fatigue53(17.3%)Chest pain11(3.6%)Chill26(8.5%)Short of breath5(1.6%)Dyspnea4(1.3%)Diarrhea16(5.2%)Headache22(7.2%)Pharyngeal discomfort44(14.3%)Flustered3(1.0%)Muscle soreness39(12.7%)Nasal congestion and runny nose19(6.2%)Nausea and vomiting11(3.6%)[^2]

3.2. Lesion distribution and features in chest CT {#sec0050}
-------------------------------------------------

Lower lobes of bilateral lungs were most affected, followed by upper lobes. The right middle lobe was not relatively easy to be involved. Chest CT had bilateral-lung lesions in more than 80% cases. Lower lobe or peripheral region were the most common distribution form of lesion, which occurred in over 75% CT scans. GGO was the most common manifestation of COVID-19 pneumonia, which was often accompanied by vascular enhancement sign. Consolidation and fibrosis were seen in almost half of all the cases. Air bronchial sign accompanied consolidation. Pleural thickening was seen in half of the cases, accompanied by fibrosis. Pleural effusion and lymphadenopathy was rare (as shown in [Table 2](#tbl0010){ref-type="table"} ).Table 2Features of chest CT scan in COVID-19 pneumonia patientsTable 2CharacteristicsN(%)Distribution Unilateral lung121(19.3%) Bilateral lungs507(80.7%) Lower lung or peripheral480(76.5%)Lung lobes involved Left upper lobe418(66.6%) Left lower lobe514(81.8%) Right upper lobe402(64%) Right middle lobe342(54.5%) Right lower lobe551(87.7%)Vascular enhancement sign416(66.2%)Air bronchial sign211(33.6%)Interlobular septal thickening372(59.2%)Pleural thickening314(50.0%)Pleural effusion16(2.5%)Lymphadenopathy17(2.7%)[^3]

3.3. Quantitative comparison of chest CT findings in three Groups {#sec0055}
-----------------------------------------------------------------

Number of lung lobes involved in Group 3 was significantly more than Group 1. Number of lung lobes involved in Group 2 had no significant difference with Group 1.

Total chest CT scores of Group 1 had significant difference with Group 2. However, there were no significant difference in scores of GGO and consolidation between every two groups (as shown in [Table 4](#tbl0020){ref-type="table"}). Scores of fibrosis in Group 1 were significantly lower than Group 2 and Group 3 (as shown in [Table 3](#tbl0015){ref-type="table"} ).Table 3Quantitative analysis of chest CT characteristics in 3 groupsTable 3Characteristics ScoreGroup 1\
(n = 273)Group 2\
(n = 255)Group 3\
(n = 100)Numbers of lung lobes involved4(2,5)4(2,5)4(3,5)Total CT Score6(3, 8)7(4, 9)6(4, 11)GGO5(2, 7)5(2, 7.75)5(3, 7)Consolidation0(0, 2)1(0, 2)0(0, 2)Fibrosis1(0, 2)1(0, 3)1.5(0, 4)[^4]Table 4Comparison of chest CT characteristics between every two groupsTable 4Group 1 vs Group 2Group 2 vs Group 3Group 1 vs Group 3PZPZPZNumbers of lung lobes involved0.221−1.2230.075−1.7780.007\*−2.687Total CT score0.006\*−2.7450.913−0.1100.052−1.947GGO score0.153−1.4290.711−0.3710.551−0.597Consolidation score0.230−1.2010.172−1.3660.592−0.536Fibrosis score0.003\*−2.9460.607−0.5140.010\*−2.572[^5]

3.4. Quantitative comparison of chest CT findings between men and women {#sec0060}
-----------------------------------------------------------------------

In the first week, fibrosis score of male patients was higher than female. In the second week, male patients had more lung lobes involved than female. Total CT score, GGO score and fibrosis score of male patients were significantly higher than female in the second week. Male patients had higher consolidation score and fibrosis score than female in the third week (as shown in [Table 5](#tbl0025){ref-type="table"} ).Table 5Comparison of chest CT characteristics between men and womenTable 51st week2nd week3rd weekPZPZPZNumbers of lung lobes involved0.696−0.3900.013\*−2.4730.096−1.664Total CT score0.063−1.8580.002\*−3.0450.051−1.948GGO score0.064−1.8500.001\*−3.2950.341−0.953Consolidation score0.921−0.990.595−0.5320.000\*−3.697Fibrosis score0.022\*−2.2920.018\*−2.3590.015\*−2.429[^6]

3.5. Correlation analysis between ABG analysis indices and CT scores {#sec0065}
--------------------------------------------------------------------

Total CT score and GGO score had weak to moderate correlation with arterial blood gas indices. Consolidation score and fibrosis score had weak correlations with partial pressure of carbon dioxide in artery. Fibrosis score had a moderate correlation with Oxygenation index (as shown in [Table 6](#tbl0030){ref-type="table"} ).Table 6Spearman rank correlation between ABG analysis indices and CT scoresTable 6Total CT scoreGGO scoreConsolidation scoreFibrosis scorePrPrPrPrPaO20.001−0.264\*0.001−0.260\*0.246−0.0950.136−0.122PaCO20.000−0.433\*0.000−0.332\*0.009−0.221\*0.001−0.272\*SaO20.029−0.184\*0.034−0.179\*0.493−0.0580.123−0.131OI0.001−0.464\*0.003−0.413\*0.241−0.1690.014−0.345\*[^7]

3.6. Therapy {#sec0070}
------------

The treatment was based on the guidelines. α-interferon inhalation combined with oral or intravenous antiviral drugs were for antiviral therapy. Antibiotics could be used if necessary.

4. Discussion {#sec0075}
=============

This was a multicenter study. 307 eligible patients in Jiangsu were enrolled in the study. 628 CT scans were analyzed in the study.

In this study, number of male patients infected with SARS-CoV-2 was slightly more than female patients, which was consistent with previous studies ([@bib0035]; [@bib0055]; [@bib0015]). Fever and cough were the main symptoms ([@bib0055]; [@bib0050]), which was consistent with previous studies, too. Low fever was a common type of fever. Dry cough was more common than expectorant. Some patients had symptoms of fatigue, chest pain, chill, short of breath, dyspnea, diarrhea, headache, pharyngeal discomfort, flustered, muscle soreness, nasal congestion, runny nose, nausea and vomiting, which were also reported in other studies ([@bib0040] [@bib0015]; [@bib0035]). 122(39.7%) patients had history of Hubei residence or travel, and 108(35.2%) patients had history of close contact with confirmed cases. Proportion of patients with a clear epidemiological history was lower than previously report in Anhui Province, another Chinese province outside Wuhan ([@bib0025]), that study was finished more than one month ago. This might be due to the decrease in imported cases in other provinces after the city was closed in Hubei. So, effective contact tracing and isolation could contribute to reducing the overall size of an outbreak or bringing it under control over a longer time period ([@bib0010]).

The lower lobes and periphery of the lungs were easily involved in COVID-19 pneumonia, this phenomenon was also seen in other studies ([@bib0020]; [@bib0040]). Right middle lung lobe was relatively rare involved, which might be due to gravity. Prone position was suggested for COVID-19 patients to help improve ventilation, which might be for the same reason.

In the third week, there was less lung lobes involved than the first week. This might indirectly suggest that it needed over 2 weeks for COVID-19 pneumonia to be absorbed. Fibrosis in the second week and the third week were more than the first week. Lesion area of lungs in the second week were bigger than the first week. In the second week, pneumonia might improve or progress in chest CT ([Figure 1](#fig0005){ref-type="fig"}, [Figure 2](#fig0010){ref-type="fig"} ). In some cases, progression or improvement of lesions could occur in the same time but in different lung lobes. Scores of GGO had no significant difference in the three weeks. In most cases, the density of GGO decreased during treatment instead of absorbing. So, the area scoring method had certain limitations.Figure 1Transverse chest HRCT scans series from a 47-year-old woman with common COVID-19 pneumonia(a) Day 2 after symptom onset: multifocal round or patchy ground-glass opacity in bilateral lower lobes. (b)Day 8 after symptom onset: multifocal irregular consolidation and fibrosis in left upper lobe and bilateral lower lobes. (c)Day 17 after symptom onset: multifocal patchy ground-glass opacity in left upper lobe and bilateral lower lobes, fibrosis in right lower lobe. (d)Day 25 after symptom onset: multifocal patchy ground-glass opacity in left upper lobe and bilateral lower lobes.Figure 1Figure 2Transverse chest HRCT scans series from a 51-year-old man with common COVID-19 pneumonia.(a) Day 3 after symptom onset: multifocal round or patchy ground-glass opacity in bilateral lower lobes and the right middle lobe. (b)Day 9 after symptom onset: Progress of patchy ground-glass opacity in right middle lobe, mixed ground-glass opacity and consolidation in bilateral lower lobes. (c)Day 15 after symptom onset: multifocal irregular consolidation and fibrosis in bilateral lower lobes and the right middle lobe. (d)Day 26 after symptom onset: patchy ground-glass opacity in right middle lobe, mixed ground-glass opacity and consolidation in bilateral lower lobes.Figure 2

Some studies had shown that male patients had longer time of virus removal than females. There was still a lack of relevant reports on the difference in CT severity between men and women. In this study, lung fibrosis of men were more than women in the first three weeks. In the second week, men had more lung lobes involved and bigger lung lesion area than women. Men had higher total CT scores and GGO scores than women in the second week. In the third week, men had more consolidation and fibrosis in lung than women. This might indirectly support that male patients recover more slowly than female.

There were different degrees of correlation between CT score and arterial blood gas analysis indices. Total CT score and GGO score had the same trend with arterial blood gas analysis indices. This was due to strong correlation between Total CT score and GGO score.

As a new coronavirus, little is known about the prognosis of COVID-19 disease ([@bib0035]). CT manifestations were considered to be posterior to clinical manifestations in the previous studies ([@bib0005]).

COVID-19 pneumonia is highly contagious disease, which is mainly spread through respiratory droplets and contact. In order to control the spread of infection, pulmonary function test was difficult to carry out. As of March 15, all cases in this study had been cured and discharged. Long-term follow-up and pulmonary function test are necessary to help us understand the recovery of lung function in COVID-19 pneumonia patients.

5. Conclusion {#sec0080}
=============

Chest CT played an important role in the diagnosis of COVID-19 pneumonia. Changes in chest CT were difficult to assess quantitatively in the first third weeks. Chest CT of male patients was more serious than female in the second. More consolidation and fibrosis lesions existed in male patients in the third week. Although CT score had correlations with arterial blood gas indices, long-term follow-up of pulmonary function test is needed to determine the recovery of lung.
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